Genflow to Attend Healthcare Conference
Rhea-AI Summary
Genflow (OTCQB:GENFF) will attend the 44th Annual J.P. Morgan Healthcare Conference on January 12–15, 2026 at the Westin St. Francis in San Francisco.
Participation aims to facilitate meetings with potential partners, institutional investors, and pharmaceutical companies as the company advances its gene‑therapy pipeline targeting the SIRT6 longevity pathway. The appearance is an investor‑relations and business‑development opportunity at a major industry event.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, GENFF declined 25.00%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among key biotechnology peers, most showed 0% change, while ZEO SCIENTIFIX INC rose 5.71%. With Genflow up 12.04% pre-news and no peers in the momentum scanner, the move appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Oct 24 | Holdings disclosure | Positive | +0.0% | Investor increased stake to 11.32% of voting rights with no price reaction. |
| Oct 22 | Patent publication | Positive | +30.4% | Second European patent application for SIRT6 variant for NASH published. |
| Oct 09 | Equity financing | Positive | +92.3% | Alternative transaction raised £440,000 via new shares and warrants to CEO and holders. |
| Oct 02 | Discounted equity issue | Negative | -48.0% | £340,000 equity raise at 0.85 pence, a 35% discount, triggered a sharp selloff. |
| Oct 02 | Equity issuance | Negative | -48.0% | Equity issue and warrants increased share count to 493,547,942, weighing on shares. |
Recent news with clear strategic or financing angles often aligned with sizeable price moves, while ownership disclosures saw little reaction.
Over the last few months, Genflow’s news flow has centered on financing, ownership changes, and intellectual property. Equity issues on Oct 2, 2025 raised £340,000 and were followed by sharp -48% price reactions, highlighting sensitivity to dilution. An alternative equity transaction on Oct 9, 2025 raising £440,000 saw a strong 92.31% gain. A second European patent application on Oct 22, 2025 coincided with a 30.4% rise, while an Oct 24 holdings disclosure had no impact. Today’s conference-attendance news fits into this pattern of strategic updates rather than capital actions.
Market Pulse Summary
The stock dropped -25.0% in the session following this news. A negative reaction despite neutral, conference-related news would fit a pattern where the stock remained sensitive to broader capital structure concerns. Historical equity issues around £340,000 and £440,000 prompted moves of -48% and 92.31%, showing how sentiment could shift sharply. Without new financing or trial data in this update, any pronounced decline likely reflected existing worries rather than the conference attendance itself.
Key Terms
gene-therapy medical
sirt6 medical
longevity pathway medical
AI-generated analysis. Not financial advice.
Genflow to Attend the 44th Annual J.P. Morgan Healthcare Conference
LONDON, UK / ACCESS Newswire / December 11, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), a leading European-based biotechnology company focusing on longevity, announces that it will attend the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12-15, 2026, at the Westin St. Francis in San Francisco, California.
J.P. Morgan's Healthcare Conference is the sector's most influential global investment gathering, connecting industry leaders, high-growth innovators, and the investment community. Genflow's participation provides an opportunity to engage with potential partners, institutional investors, and pharmaceutical companies as the Company advances its gene-therapy pipeline targeting the SIRT6 longevity pathway.
About the 44th Annual J.P. Morgan Healthcare Conference
The 44th Annual J.P. Morgan Healthcare Conference is the largest and most informative healthcare investment symposium in the industry, bringing together global industry leaders, emerging growth companies, technology innovators, and investors. More information is available on the conference website.
Dr. Eric Leire, CEO of Genflow, commented: "We're excited to attend the JP Morgan Healthcare Conference in San Francisco this January. Our planned meetings reflect our current focus on lipid nanoparticle delivery for mRNA SIRT6 therapeutics, which is opening compelling opportunities for strategic partnerships in the longevity space."
Contacts
Genflow Biosciences | Harbor Access |
Dr Eric Leire, CEO | Jonathan Paterson, Investor Relations |
+32-477-495-881 | +1 475 477 9401 |
About Genflow Biosciences
Founded in 2020, Genflow Biosciences Plc. (LSE:GENF)(OTCQB:GENFF), a biotechnology company headquartered in the UK with R&D facilities in Belgium, is pioneering gene therapies to decelerate the aging process, with the goal of promoting longer and healthier lives while mitigating the financial, emotional, and social impacts of a fast-growing aging global population. Genflow's lead compound, GF-1002, works through the delivery of a centenarian variant of the SIRT6 gene which has yielded promising preclinical results. Genflow's 12-month proof-of-concept clinical trial evaluating their SIRT6-centenarian gene therapy in aged dogs began in March 2025. Other programs, include a clinical trial that will explore the potential benefits of GF-1002 in treating MASH (Metabolic Dysfunction-Associated Steatohepatitis), the most prevalent chronic liver disease for which there is no effective treatments. Please visit www.genflowbio.com and follow the Company on LinkedIn and X.
DISCLAIMER
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
When will Genflow (GENFF) attend the J.P. Morgan Healthcare Conference?
Where will Genflow (GENFF) be presenting at the J.P. Morgan Healthcare Conference?
What is Genflow (GENFF) expected to discuss at the J.P. Morgan Healthcare Conference?
How can investors arrange meetings with Genflow (GENFF) at the conference?
Will Genflow (GENFF) announce data or new deals at the January 2026 conference?
Why is attending the J.P. Morgan Healthcare Conference important for Genflow (GENFF)?
